Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances

다국어 초록 (Multilingual Abstract)

Kidney disease is becoming a global public health issue. Acute kidney injury (AKI) and chronic kidney disease (CKD) have serious adverse health outcomes. However, there is no effective therapy to treat these diseases. Lactoferrin (LF), a multi-functional glycoprotein, is protective against various pathophysiological conditions in various disease models. LF shows protective effects against AKI and CKD. LF reduces markers related to inflammation, oxidative stress, apoptosis, and kidney fibrosis, and induces autophagy and mitochondrial biogenesis in the kidney. Although there are no clinical trials of LF to treat kidney disease, several clinical trials and studies on LF-based drug development are ongoing. In this review, we discussed the possible kidney protective mechanisms of LF, as well as the pharmacological and therapeutic advances. The evidence suggests that LF may become a potent pharmacological agent to treat kidney diseases.

목차 (Table of Contents)

• INTRODUCTION METHODS STRUCTURE AND RECEPTORS OF LACTOFERRIN PROTECTIVE EFFECTS OF LACTOFERRIN AGAINST KIDNEY DISEASES PHARMACOLOGICAL POTENTIALS OF LACTOFERRIN AGAINST VARIOUS PATHOPHYSIOLOGICAL CONDITIONS IN KIDNEY DISEASES UPDATES ON CLINICAL TRIALS LACTOFERRIN-BASED DRUG DEVELOPMENT CONCLUSIONS FUNDING ACKNOWLEDGEMENTS CONFLICTS OF INTEREST REFERENCES

참고문헌 (Reference)

1 Singh A, "Whey protein and its components lactalbumin and lactoferrin affect energy balance and protect against stroke onset and renal damage in salt-loaded, high-fat fed male spontaneously hypertensive stroke-prone rats" 150 : 763-774, 2020

2 Betteridge DJ., "What is oxidative stress?" 49 (49): 3-8, 2000

3 Saito H, "Toxico-pharmacological perspective of the Nrf2-Keap1defense system against oxidative stress in kidney diseases" 85 : 865-872, 2013

4 Pan T, "The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease" 131 (131): 1969-1978, 2008

5 Serhan CN, "The resolution of inflammation : the devil in the flask and in the details" 25 : 1441-1448, 2011

6 Rawat P, "The multifunctional glycolytic protein glyceraldehyde-3-phosphate dehydrogenase(GAPDH)is a novel macrophage lactoferrin receptor" 90 : 329-338, 2012

7 Wick G, "The immunology of fibrosis" 31 : 107-135, 2013

8 Sinopoli A, "The effects of orally administered lactoferrin in the prevention and management of viral infections : a systematic review" 2021

9 White E, "The double-edged sword of autophagy modulation in cancer" 15 : 5308-5316, 2009

10 Couser WG, "The contribution of chronic kidney disease to the global burden of major noncommunicable diseases" 80 : 1258-1270, 2011

11 Fernandes KE, "The antifungal activity of lactoferrin and its derived peptides : mechanisms of action and synergy with drugs against fungal pathogens" 8 : 2-, 2017

12 Sørensen M, "The Proteins in whey" Hagerup in Komm 3-9, 1939

13 Karav S, "Studying lactoferrin N-glycosylation" 18 : 870-, 2017

14 Fan J, "Roles of inflammasomes in inflammatory kidney diseases" 2019 : 2923072-, 2019

15 Kim JA, "Role of mitochondrial dysfunction in insulin resistance" 102 : 401-414, 2008

16 Takayama Y, "Role of CXC chemokine receptor type 4 as a lactoferrin receptor" 95 : 57-63, 2017

17 Panzer U, "Resolution of renal inflammation : a new role for NF-kappaB1(p50)in inflammatory kidney diseases" 297 : F429-, 2009

18 Shimmura S, "Reoxygenation injury in a cultured corneal epithelial cell line protected by the uptake of lactoferrin" 39 : 1346-1351, 1998

19 Hegazy R, "Renoprotective effect of lactoferrin against chromium-induced acute kidney injury in rats : involvement of IL-18 and IGF-1 inhibition" 11 : e0151486-, 2016

20 Liu Y, "Renal fibrosis : new insights into the pathogenesis and therapeutics" 69 : 213-217, 2006

21 Efstratiadis G, "Renal fibrosis" 13 : 224-229, 2009

22 Jones DP, "Redefining oxidative stress" 8 : 1865-1879, 2006

23 Guo C, "Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice" 11 : 7183-7196, 2020

24 Conesa C, "Recombinant human lactoferrin : a valuable protein for pharmaceutical products and functional foods" 28 : 831-838, 2010

25 Shin K, "Recombinant human intelectin binds bovine lactoferrin and its peptides" 31 : 1605-1608, 2008

26 Fillebeen C, "Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier" 274 : 7011-7017, 1999

27 Taniyama Y, "Reactive oxygen species in the vasculature : molecular and cellular mechanisms" 42 : 1075-1081, 2003

28 Kimoto Y, "Protective effect of lactoferrin on cisplatin-induced nephrotoxicity in rats" 75 : 159-164, 2013

29 Onishi H, "Preparation of chitosan/alginate/calcium complex microparticles loaded with lactoferrin and their efficacy on carrageenan-induced edema in rats" 36 : 879-884, 2010

30 Koyama K, "Preparation and in vitro evaluation of chitosan-coated alginate/calcium complex microparticles loaded with fluorescein-labeled lactoferrin" 129 : 1507-1514, 2009

31 Onishi H, "Preparation and in vitro characteristics of lactoferrin-loaded chitosan microparticles" 33 : 641-647, 2007

32 Nathan C, "Points of control in inflammation" 420 : 846-852, 2002

33 Jonasch E, "Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma" 113 : 72-77, 2008

34 Uddin MJ, "Pharmacotherapy against oxidative stress in chronic kidney disease : promising small molecule natural products targeting Nrf2-HO-1 signaling" 10 : 258-, 2021

35 Basile DP, "Pathophysiology of acute kidney injury" 2 : 1303-1353, 2012

36 Modaresi A, "Oxidative stress in chronic kidney disease" 9 : 165-179, 2015

37 Sies H, "Oxidative stress and vascular disease" Springer 1-8, 2000

38 Sureshbabu A, "Oxidative stress and autophagy : crucial modulators of kidney injury" 4 : 208-214, 2015

39 Finaud J, "Oxidative stress : relationship with exercise and training" 36 : 327-358, 2006

40 Burton GJ, "Oxidative stress" 25 : 287-299, 2011

41 RatliffBB, "Oxidant mechanisms in renal injury and disease" 25 : 119-146, 2016

42 Medzhitov R, "Origin and physiological roles of inflammation" 454 : 428-435, 2008

43 Yao X, "Oral delivery of lactoferrin : a review" 19 : 125-134, 2013

44 Klahr S, "Obstructive nephropathy and renal fibrosis" 283 : F861-F875, 2002

45 Jeong BY, "Novel plasminogen activator inhibitor-1 inhibitors prevent diabetic kidney injury in a mouse model" 11 : e0157012-, 2016

46 van Dijk MA, "No effect of enalapril on progression in autosomal dominant polycystic kidney disease" 18 : 2314-2320, 2003

47 Zhang Y, "Nbr1-regulated autophagy in Lactoferrin-induced osteoblastic differentiation" 84 : 1191-1200, 2020

48 Balcão VM, "Nanoencapsulation of bovine lactoferrin for food and biopharmaceutical applications" 32 : 425-431, 2013

49 Gupta I, "Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism" 10 : 1289-1314, 2015

50 Raei M, "Nano-encapsulation of isolated lactoferrin from camel milk by calcium alginate and evaluation of its release" 79 : 669-673, 2015

51 Griendling KK, "NAD(P)H oxidase : role in cardiovascular biology and disease" 86 : 494-501, 2000

52 Furmanski P, "Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity" 170 : 415-429, 1989

53 Kanwar JR, "Multimodal iron oxide(Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative(ER(-)/PR(-)/HER2(-))" 11 : 249-268, 2016

54 Beal MF, "Mitochondrial dysfunction in neurodegenerative diseases" 1366 : 211-223, 1998

55 Emma F, "Mitochondrial dysfunction in inherited renal disease and acute kidney injury" 12 : 267-280, 2016

56 Wei PZ, "Mitochondrial dysfunction in diabetic kidney disease" 496 : 108-116, 2019

57 Ballinger SW, "Mitochondrial dysfunction in cardiovascular disease" 38 : 1278-1295, 2005

58 Modica-Napolitano JS, "Mitochondrial dysfunction in cancer" 4 : 755-762, 2004

59 Madamanchi NR, "Mitochondrial dysfunction in atherosclerosis" 100 : 460-473, 2007

60 Lowell BB, "Mitochondrial dysfunction and type 2 diabetes" 307 : 384-387, 2005

61 Jiang M, "Mitochondrial dysfunction and the AKI-to-CKD transition" 319 : F1105-F1116, 2020

62 Pieczenik SR, "Mitochondrial dysfunction and molecular pathways of disease" 83 : 84-92, 2007

63 Nicolson GL, "Mitochondrial dysfunction and chronic disease : treatment with natural supplements" 13 : 35-43, 2014

64 Maekawa H, "Mitochondrial damage causes inflammation via cGAS-STING signaling in acute kidney injury" 29 : 1261-1273, 2019

65 Duann P, "Mitochondria damage and kidney disease" 982 : 529-551, 2017

66 Humphreys BD, "Mechanisms of renal fibrosis" 80 : 309-326, 2018

67 Suzuki YA, "Mammalian lactoferrin receptors : structure and function" 62 : 2560-2575, 2005

68 Trif M, "Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases" 226 : 559-564, 2001

69 Roseanu A, "Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells" 23 : 485-492, 2010

70 Ishikado A, "Liposomalization of lactoferrin enhanced it's anti-inflammatory effects via oral administration" 28 : 1717-1721, 2005

71 Gao CH, "Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2-into M1-like phenotype" 9 : 37-, 2018

72 Elzoghby AO, "Lactoferrin, a multi-functional glycoprotein : active therapeutic, drug nanocarrier & targeting ligand" 263 : 120355-, 2020

73 Yen CC, "Lactoferrin protects hyperoxia-induced lung and kidney systemic inflammation in an in vivo imaging model of NF-κB/luciferase transgenic mice" 22 : 526-538, 2020

74 Park YG, "Lactoferrin protects against prion proteininduced cell death in neuronal cells by preventing mitochondrial dysfunction" 31 : 325-330, 2013

75 Aizawa S, "Lactoferrin promotes autophagy via AMP-activated protein kinase activation through low-density lipoprotein receptor-related protein 1" 493 : 509-513, 2017

76 Kruzel ML, "Lactoferrin in a context of inflammation-induced pathology" 8 : 1438-, 2017

77 Ibuki M, "Lactoferrin has a therapeutic effect via HIF inhibition in a murine model of choroidal neovascularization" 11 : 174-, 2020

78 van de Looij Y, "Lactoferrin during lactation protects the immature hypoxic-ischemic rat brain" 1 : 955-967, 2014

79 Kruzel ML, "Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model" 16 : 67-79, 2010

80 Hsu YH, "Lactoferrin contributes a renoprotective effect in acute kidney injury and early renal fibrosis" 12 : 434-, 2020

81 Nojima Y, "Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol)has an improved circulating halflife" 26 : 2125-2132, 2009

82 Actor JK, "Lactoferrin as a natural immune modulator" 15 : 1956-1973, 2009

83 Li D, "Lactoferrin alleviates acute alcoholic liver injury by improving redox-stress response capacity in female C57BL/6J mice" 69 : 14856-14867, 2021

84 García-Montoya IA, "Lactoferrin a multiple bioactive protein : an overview" 1820 : 226-236, 2012

85 Ahmed KA, "Lactoferrin : potential functions, pharmacological insights, and therapeutic promises" 4 : 223-237, 2021

86 Hao L, "Lactoferrin : major physiological functions and applications" 20 : 139-144, 2019

87 Drago-Serrano ME, "Lactoferrin : balancing ups and downs of inflammation due to microbial infections" 18 : 501-, 2017

88 Adlerova L, "Lactoferrin : a review" 53 : 457-468, 2008

89 Meng Q, "Intranasal delivery of Huperzine A to the brain using lactoferrinconjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease" 13 : 705-718, 2018

90 Iigo M, "Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine" 27 : 1017-1029, 2014

91 Lang J, "Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans" 6 : e23710-, 2011

92 Meng XM, "Inflammatory processes in renal fibrosis" 10 : 493-503, 2014

93 Ozbek E, "Induction of oxidative stress in kidney" 2012 : 465897-, 2012

94 Knudsen KB, "In vivo toxicity of cationic micelles and liposomes" 11 : 467-477, 2015

95 Ernandez T, "Immunoregulatory role of TNFalpha in inflammatory kidney diseases" 76 : 262-276, 2009

96 Shi P, "Identification and mechanism of peptides with activity promoting osteoblast proliferation from bovine lactoferrin" 22 : 19-25, 2018

97 Ando K, "Human lactoferrin activates NF-kappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling" 277 : 2051-2066, 2010

98 Milewska A, "Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells" 88 : 13221-13230, 2014

99 Hill NR, "Global prevalence of chronic kidney disease-a systematic review and meta-analysis" 11 : e0158765-, 2016

100 Qari SH, "Gene expression of renal lactoferrin and glycemic homeostasis in diabetic rats with reference to the protective role of exogenous bovine lactoferrin" 81 : 12-, 2020

101 Güçer S, "Focal segmental glomerulosclerosis associated with mitochondrial cytopathy : report of two cases with special emphasis on podocytes" 8 : 710-717, 2005

102 Kanwar JR, "Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc" 10 : 35-55, 2015

103 Abrink M, "Expression of lactoferrin in the kidney : implications for innate immunity and iron metabolism" 57 : 2004-2010, 2000

104 Inagi R, "Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury" 112 : e1-e9, 2009

105 Lin JH, "Endoplasmic reticulum stress in disease pathogenesis" 3 : 399-425, 2008

106 Hotamisligil GS, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease" 140 : 900-917, 2010

107 Gallazzini M, "Endoplasmic reticulum stress and kidney dysfunction" 110 : 205-216, 2018

108 Xu C, "Endoplasmic reticulum stress : cell life and death decisions" 115 : 2656-2664, 2005

109 Agostinis P, "Encyclopedia of cancer" Springer Berlin Heidelberg 1240-1244, 2011

110 Bikbov B, "Disparities in chronic kidney disease prevalence among males and females in 195 countries : analysis of the global burden of disease 2016 study" 139 : 313-318, 2018

111 Nojima Y, "Development of poly(ethylene glycol)conjugated lactoferrin for oral administration" 19 : 2253-2259, 2008

112 Sohn M, "Delayed treatment with fenofibrate protects against highfat diet-induced kidney injury in mice : the possible role of AMPK autophagy" 312 : F323-F334, 2017

113 Pabla N, "Cisplatin nephrotoxicity : mechanisms and renoprotective strategies" 73 : 994-1007, 2008

114 Joe Y, "Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis" 309 : G21-G29, 2015

115 Levey AS, "Chronic kidney disease" 379 : 165-180, 2012

116 Liu Y, "Cellular and molecular mechanisms of renal fibrosis" 7 : 684-696, 2011

117 Majno G, "Cells, tissues, and disease: principles of general pathology" Oxford University Press; 2004

118 Wei X, "Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response" 25 : 237-253, 2015

119 Schrier R, "Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease : results of a seven-year prospective randomized study" 13 : 1733-1739, 2002

120 Zheng M, "Carbon monoxide-releasing molecules reverse leptin resistance induced by endoplasmic reticulum stress" 304 : E780-E788, 2013

121 Md Jamal Uddin ; 박은선 ; 하헌주, "Carbon monoxide releasing molecule-2 protects mice against acute kidney injury through inhibition of ER stress" 대한약리학회 22 (22): 567-575, 2018

122 Arab HH, "Camel milk ameliorates 5-fluorouracil-induced renal injury in rats : targeting MAPKs, NF-κB and PI3K/Akt/eNOS pathways" 46 : 1628-1642, 2018

123 Ammendolia MG, "Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells" 76 : 252-262, 2007

124 Okazaki Y, "Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats" 51 : 84-90, 2012

125 Halliwell B, "Biochemistry of oxidative stress" 35 (35): 1147-1150, 2007

126 Kimura T, "Autophagy protects the proximal tubule from degeneration and acute ischemic injury" 22 : 902-913, 2011

127 Ding Y, "Autophagy in diabetic nephropathy" 224 : R15-R30, 2015

128 Lin TA, "Autophagy in chronic kidney diseases" 8 : 61-, 2019

129 Mariño G, "Autophagy for tissue homeostasis and neuroprotection" 23 : 198-206, 2011

130 Stern ST, "Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity" 9 : 20-, 2012

131 Kimura T, "Autophagy and kidney inflammation" 13 : 997-1003, 2017

132 Ichimiya T, "Autophagy and autophagy-related diseases : a review" 21 : 8974-, 2020

133 Brest P, "Autophagy and Crohn's disease : at the crossroads of infection, inflammation, immunity, and cancer" 10 : 486-502, 2010

134 Mizushima N, "Autophagy : process and function" 21 : 2861-2873, 2007

135 Kelekar A, "Autophagy" 1066 : 259-271, 2005

136 Meijer E, "Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease : a cross-sectional analysis" 56 : 883-895, 2010

137 Jiang R, "Apo-and holo-lactoferrin are both internalized by lactoferrin receptor via clathrinmediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells" 226 : 3022-3031, 2011

138 Rojas-Rivera J, "Antioxidants in kidney diseases : the impact of bardoxolone methyl" 2012 : 321714-, 2012

139 Belizi S, "Antioxidant properties of lactoferrin from human milk" 127 : 471-473, 1999

140 Jenssen H, "Antimicrobial properties of lactoferrin" 91 : 19-29, 2009

141 Kato K, "Amino group PEGylation of bovine lactoferrin by linear polyethylene glycol-pnitrophenyl active esters" 33 : 1253-1255, 2010

142 Chen HL, "Aerosolized bovine lactoferrin reduces lung injury and fibrosis in mice exposed to hyperoxia" 27 : 1057-1068, 2014

143 Ronco C, "Acute kidney injury" 394 : 1949-1964, 2019

144 Jager KJ, "A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases" 34 : 1803-1805, 2019

145 Kwon G, "A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice : possible role of peroxisomal and mitochondrial biogenesis" 8 : 74217-74232, 2017

146 Akiyama Y, "A lactoferrin-receptor, intelectin 1, affects uptake, sub-cellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells" 154 : 437-448, 2013

147 Raghavan S, "A comparative study on the cellular stressors in mesenchymal stem cells(MSCs)and pancreatic β-cells under hyperglycemic milieu" 476 : 457-469, 2021